What Is Myasthenia Gravis?
Myasthenia gravis is a disease of the neuromuscular junction — the specialised interface between a nerve and the muscle it controls. In a healthy dog, nerve signals cause the release of a chemical messenger called acetylcholine, which crosses the junction and binds to receptors on the muscle surface, triggering contraction. In myasthenia gravis, the immune system produces antibodies that target and destroy these acetylcholine receptors (AChR). With fewer functional receptors available, the muscle receives a weaker signal and tires rapidly.
The result is characteristic: muscle weakness that worsens with exercise and temporarily improves with rest. The weakness can affect voluntary muscles throughout the body, but in dogs the pattern of involvement leads to two clinically distinct forms of the disease.
Acquired versus Congenital Myasthenia Gravis
The vast majority of cases in dogs are acquired — the antibody-mediated immune attack develops during the dog's lifetime, most commonly in young adults and again in older dogs. There is a bimodal age distribution, with peaks in dogs between one and four years and again between nine and thirteen years.
A congenital form also exists, caused by an inherited defect in acetylcholine receptors rather than an immune-mediated attack. This form is far less common, presents in very young animals, and does not respond to immune-modulating treatments.
The Focal Form: Megaoesophagus
In the focal form of myasthenia gravis, weakness is confined to specific muscle groups rather than being generalised. The oesophagus is the most commonly and severely affected structure. The oesophagus in dogs is almost entirely composed of striated (voluntary) muscle — unlike in humans and cats — which makes it uniquely vulnerable to the effects of AChR loss.
Megaoesophagus
When oesophageal muscle weakness is severe, the oesophagus loses its ability to contract and propel food and water down to the stomach. It dilates abnormally, becoming a flaccid, distended tube — a condition known as megaoesophagus. Food and liquid pool in the distended oesophagus rather than passing into the stomach.
Regurgitation
The hallmark clinical sign of megaoesophagus is regurgitation — the passive effortless return of undigested food from the oesophagus, often shortly after eating. Owners frequently describe finding tubular masses of food on the floor or furniture. This is distinct from vomiting, which involves active abdominal contractions and the return of stomach contents. Regurgitation in myasthenia gravis may occur minutes to hours after a meal, depending on how distended the oesophagus has become.
Aspiration Pneumonia
The most serious complication of megaoesophagus — and the most common cause of death in affected dogs — is aspiration pneumonia. Regurgitated material, or fluid that pools in the dilated oesophagus, can be inhaled into the airways and lungs. This leads to bacterial infection of the lung tissue, producing coughing, difficulty breathing, fever, and in severe cases, life-threatening respiratory compromise. Aspiration pneumonia must be identified and treated aggressively with antibiotics, and preventing further aspiration is central to the management of these patients.
The focal form of myasthenia gravis can present without any obvious limb weakness, making megaoesophagus with regurgitation the primary — and sometimes only — complaint. This means the condition can be overlooked unless specifically considered as a differential diagnosis.
The Generalised Form
In generalised myasthenia gravis, weakness affects skeletal muscles throughout the body. Dogs typically show exercise intolerance — they tire quickly on walks and may collapse after modest exertion. The weakness typically improves after a period of rest, only to recur with further exercise. In severe cases, dogs may be unable to walk at all. The hindlimbs are often more severely affected than the forelimbs. Megaoesophagus is commonly present alongside generalised weakness, and facial muscle involvement may cause a drooping expression. The voice may also change if the laryngeal muscles are affected.
An acute fulminating form exists in which dogs develop rapidly progressive, profound weakness and respiratory failure — this constitutes a true emergency requiring intensive care.
Diagnosis: The Acetylcholine Receptor Antibody Titre
The definitive diagnostic test for acquired myasthenia gravis is measurement of the acetylcholine receptor antibody titre in the blood. This test detects the circulating antibodies responsible for receptor destruction and is both highly sensitive and specific. A positive result — particularly when combined with a compatible clinical presentation — confirms the diagnosis.
The test is performed at specialist laboratories; the Comparative Neuromuscular Laboratory at the University of California, San Diego, is the reference laboratory most widely used in Europe and North America. It is important to note that a small proportion of dogs with myasthenia gravis are seronegative — they test negative despite having the disease — so a negative result does not entirely exclude the diagnosis in a highly suspicious case.
Thoracic radiographs are essential in all suspected cases to assess for megaoesophagus (seen as abnormal dilation and air within the oesophagus) and to evaluate the lungs for aspiration pneumonia. Chest X-rays should be repeated regularly during treatment to monitor both conditions.
In some dogs, myasthenia gravis occurs secondary to another disease — thymoma (a tumour of the thymus gland) being the most important. Thoracic imaging should therefore also specifically assess the cranial mediastinum for a thymic mass.
Treatment
Pyridostigmine
The primary treatment for myasthenia gravis is pyridostigmine bromide, an acetylcholinesterase inhibitor. By inhibiting the enzyme that breaks down acetylcholine in the neuromuscular junction, pyridostigmine prolongs the availability of acetylcholine and allows it to compensate partially for the reduced number of functional receptors. The result is improved muscle strength. Pyridostigmine is given orally, usually two to three times daily, and the dose is adjusted to achieve the best balance of efficacy and side effects — which can include hypersalivation, vomiting, diarrhoea, and muscle tremors if the dose is too high.
Immunosuppression
In dogs that do not respond adequately to pyridostigmine alone, immunosuppressive drugs may be added to reduce the production of the damaging antibodies. This must be approached cautiously in dogs with aspiration pneumonia, as immunosuppression can worsen infection.
Management of Megaoesophagus
Dogs with megaoesophagus require specific dietary management. Feeding in an upright position — using a Bailey chair or similar device that holds the dog vertical during and for thirty minutes after eating — uses gravity to assist food passage into the stomach and dramatically reduces aspiration risk. Food consistency (wet food, meatballs, or liquid slurries) is adjusted to whichever form passes most effectively for the individual dog.
Prognosis
The prognosis for acquired myasthenia gravis is variable. A proportion of dogs — particularly those without severe megaoesophagus — undergo spontaneous remission within months as the immune attack self-resolves. Others require long-term medication. The AChR antibody titre, measured serially, is a useful guide to disease activity and response to treatment. Dogs that develop severe aspiration pneumonia have a significantly guarded prognosis. With attentive nursing, appropriate feeding management, and prompt treatment of complications, many dogs with myasthenia gravis live fulfilling lives.